Table 2 Basic characteristics between 5-ARIs User and comparison groups with Upper Tract Urothelial Carcinoma (n = 1199)
From: 5α-reductase inhibitors impact prognosis of urothelial carcinoma
5-ARIs User, n (%) | None User, n (%) | P-value | |
|---|---|---|---|
Case No. | 109 | 1090 | |
Variables | |||
Age (Mean ± SD) | 75.42 (±7.56) | 75.75 (±7.62) | 0.668 |
Age category (n, %) | |||
< 65 | 5 (4.59) | 87 (7.98) | |
65–74 | 44 (40.37) | 366 (33.58) | |
> 75 | 60 (55.05) | 637 (58.44) | |
CCI score (Mean ± SD) | 4.84 (±2.55) | 4.68 (±2.40) | 0.501 |
CCI score category | |||
0 ~ 3 | 38 (34.86) | 390 (35.78) | |
4 ~ 7 | 55 (50.46) | 547 (50.18) | |
8+ | 16 (14.68) | 153 (14.04) | |
Comorbidity | |||
Hypertension | 57 (52.29) | 553 (50.73) | 0.756 |
Hyperlipidemia | 24 (22.02) | 227 (20.83) | 0.770 |
Diabetes mellitus | 31 (28.44) | 292 (26.79) | 0.711 |
Chronic Kidney Disease | 17 (15.60) | 169 (15.50) | 0.980 |